OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press17610.17650/1818-8346-2016-11-1-8-13HEMATOLOGIC MALIGNANCIES: DIAGNOSIS, TREATMENT, SUPPORTIVE CAREГЕМОБЛАСТОЗЫ: ДИАГНОСТИКА, ЛЕЧЕНИЕ, СОПРОВОДИТЕЛЬНАЯ ТЕРАПИЯBrentuximab vedotin in children and adolescents with Hodgkin’s lymphoma and anaplastic large cell lymphoma – literature review and own experienceПрименение брентуксимаба ведо тина у детей и подростков с лимфомой Ходжкина и анапластической крупноклеточной лимфомой – обзор литературы и собственные наблюденияMyakovaN. V.МяковаН. В.
Russian Federation
nmiakova@mail.ruEvstratovD. A.ЕвстратовД. А.
Russian Federation
AbramovD. S.АбрамовД. С.
Russian Federation
KonovalovD. M.КоноваловД. М.
Russian Federation
PshonkinA. V.ПшонкинА. В.
Russian Federation
LitvinovD. V.ЛитвиновД. В.
Russian Federation
Federal Research Institute of Pediatric Hematology, Oncology and Immunology named after Dmitry Rogachev, Ministry of Health of RussiaФГБУ «Федеральный научно-клинический центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России1 Samory Mashela St., Moscow, 117198, RussiaРоссия, 117198, Москва, ул. Саморы Машела, 1310320161118133103201631032016https://oncohematology.abvpress.ru/ongm/article/view/176

Despite significant advances in the treatment of lymphomas in children remain a small proportion of patients with refractory or recurrent disease. An effective approach to the treatment of such patients – not only is the second line chemotherapy, but the use of the new targeted therapies. An example of this approach is the use of brentuximab vedotin (antibody-drug conjugate directed to the CD30) in relapsed Hodgkin’s lymphoma and anaplastic large cell lymphoma. Literature review and own experience of using this drug in children are describes in this article.

Несмотря на значительные успехи в лечении лимфом у детей, у небольшой части пациентов заболевание остается рефрактерным или рецидивирует. Эффективный подход к лечению таких больных – это не только 2-я линия химиотерапии, но и применение новых таргетных препаратов. Примером такой тактики является использование брентуксимаба ведотина – химиоиммуноконъюгата CD30 – при рецидивах лимфомы Ходжкина и анапластической крупноклеточной лимфомы. В статье приводится описание опыта применения этого препарата у детей и обзор литературы.

Hodgkin’s lymphomaimmunohistochemistryrefractoryCD30brentuximab vedotinanaplastic large cell lymphomaлимфома ХоджкинаиммуногистохимиярефрактерностьCD30брентуксимаб ведотинанапластическая крупноклеточная лимфома1. Khouri I. F., Saliba R. M., Hosing C. et al. Concurrent administration of high-dose rituximab before and after autologous stemcell transplantation for relapsed aggressive B- cell non-Hodgkin’s lymphomas. J Clin Oncol 2005;23(10):2240–7.Khouri I. F., Saliba R. M., Hosing C. et al. Concurrent administration of high-dose rituximab before and after autologous stemcell transplantation for relapsed aggressive B- cell non-Hodgkin’s lymphomas. J Clin Oncol 2005;23(10):2240–7.2. Ansell S. M., Geyer S. M., Maurer M. J. et al. Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non- Hodgkin’s lymphoma patients. Clin Cancer Res 2006;12(20 Pt 1):6056–63.Ansell S. M., Geyer S. M., Maurer M. J. et al. Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non- Hodgkin’s lymphoma patients. Clin Cancer Res 2006;12(20 Pt 1):6056–63.3. Khan K. D., Emmanouilides C., Benson D. M. Jr et al. A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximabrefractory indolent non-Hodgkin’s lymphoma. Clin Cancer Res 2006;12(23):7046–53.Khan K. D., Emmanouilides C., Benson D. M. Jr et al. A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximabrefractory indolent non-Hodgkin’s lymphoma. Clin Cancer Res 2006;12(23):7046–53.4. Teicher B. A., Chari R. V. Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res 2011;17(20):6389–97.Teicher B. A., Chari R. V. Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res 2011;17(20):6389–97.5. Fisher R. I., Kaminski M. S., Wahl R. L. et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin’s lymphomas. J Clin Oncol 2005;23(30):7565–73.Fisher R. I., Kaminski M. S., Wahl R. L. et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin’s lymphomas. J Clin Oncol 2005;23(30):7565–73.6. Morschhauser F., Radford J., Van Hoof A. et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008;26(32): 5156–64.Morschhauser F., Radford J., Van Hoof A. et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008;26(32): 5156–64.7. Locksley R. M., Killeen N., Lenardo M. J. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001;104(4):487–501.Locksley R. M., Killeen N., Lenardo M. J. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001;104(4):487–501.8. Younes A., Kadin M. E. Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy. J Clin Oncol 2003;21(18): 3526–34.Younes A., Kadin M. E. Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy. J Clin Oncol 2003;21(18): 3526–34.9. Wang C. Y., Mayo M. W., Korneluk R. G. et al. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998;281(5383):1680–3.Wang C. Y., Mayo M. W., Korneluk R. G. et al. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998;281(5383):1680–3.10. Younes A., Aggarwall B. B. Clinical implications of the tumor necrosis factor family in benign and malignant hematologic disorders. Cancer 2003;98(3):458–67.Younes A., Aggarwall B. B. Clinical implications of the tumor necrosis factor family in benign and malignant hematologic disorders. Cancer 2003;98(3):458–67.11. Nadali G., Tavecchia L., Zanolin E. et al. Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin’s disease at high risk of unfavorable outcome. Blood 1998;91(8):3011–6.Nadali G., Tavecchia L., Zanolin E. et al. Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin’s disease at high risk of unfavorable outcome. Blood 1998;91(8):3011–6.12. Katz J., Janik J. E., Younes A. Brentuximab vedotin(SGN-35). Clin Cancer Res 2011;17(20):6428–36.Katz J., Janik J. E., Younes A. Brentuximab vedotin(SGN-35). Clin Cancer Res 2011;17(20):6428–36.13. Younes A. CD30-targeted antibody therapy. Curr Opin Oncol 2011;23(6): 587–93.Younes A. CD30-targeted antibody therapy. Curr Opin Oncol 2011;23(6): 587–93.14. Edinger J. T., Clark B. Z., Pucevich B. E. et al. CD30 expression and proliferative fraction in nontransformed mycosis fungoides. Am J Surg Pathol 2009;33(12):1860–8.Edinger J. T., Clark B. Z., Pucevich B. E. et al. CD30 expression and proliferative fraction in nontransformed mycosis fungoides. Am J Surg Pathol 2009;33(12):1860–8.15. Küppers R. The biology of Hodgkin’s lymphoma. Nat Rev Cancer 2009;9(1): 15–27.Küppers R. The biology of Hodgkin’s lymphoma. Nat Rev Cancer 2009;9(1): 15–27.16. Schmitz N., Pfistner B., Sextro M. et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet 2002;359(9323):2065–71.Schmitz N., Pfistner B., Sextro M. et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet 2002;359(9323):2065–71.17. Kuruvilla J., Keating A., Crump M. How I treat relapsed and refractory Hodgkin lymphoma. Blood 2011;117(16):4208–17.Kuruvilla J., Keating A., Crump M. How I treat relapsed and refractory Hodgkin lymphoma. Blood 2011;117(16):4208–17.18. Burroughs L. M., O’Donnell P. V., Sandmaier B. M. et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 2008;14(11):1279–87.Burroughs L. M., O’Donnell P. V., Sandmaier B. M. et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 2008;14(11):1279–87.19. Merkel O., Hamacher F., Sifft E. et al. Novel therapeutic options in anaplastic large cell lymphoma: molecular targets and immunological tools. Mol Cancer Ther 2011;10(7):1127–36.Merkel O., Hamacher F., Sifft E. et al. Novel therapeutic options in anaplastic large cell lymphoma: molecular targets and immunological tools. Mol Cancer Ther 2011;10(7):1127–36.20. Amin H. M., Lai R. Pathobiology of ALK+ anaplastic large-cell lymphoma. Blood 2007;110(7):2259–67.Amin H. M., Lai R. Pathobiology of ALK+ anaplastic large-cell lymphoma. Blood 2007;110(7):2259–67.21. Vaklavas C., Forero-Torres A. Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Ther Adv Hematol 2012;3(4):209–25.Vaklavas C., Forero-Torres A. Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Ther Adv Hematol 2012;3(4):209–25.22. Wahl A. F., Klussman K., Thompson J. D. et al. The anti-CD30 monoclonal antibody SGN- 30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin’s disease. Cancer Res 2002;62(13): 3736–42.Wahl A. F., Klussman K., Thompson J. D. et al. The anti-CD30 monoclonal antibody SGN- 30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin’s disease. Cancer Res 2002;62(13): 3736–42.23. Oflazoglu E., Kissler K. M., Sievers E. L. et al. Combination of the anti-CD30- auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma. Br J Haematol 2008;142(1):69–73.Oflazoglu E., Kissler K. M., Sievers E. L. et al. Combination of the anti-CD30- auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma. Br J Haematol 2008;142(1):69–73.24. Sutherland M. S., Sanderson R. J., Gordon K. A. et al. Lysosomal trafficking and cysteine protease metabolism confer targetspecific cytotoxicity by peptide-linked anti- CD30-auristatin conjugates. J Biol Chem 2006;281(15):10540–7.Sutherland M. S., Sanderson R. J., Gordon K. A. et al. Lysosomal trafficking and cysteine protease metabolism confer targetspecific cytotoxicity by peptide-linked anti- CD30-auristatin conjugates. J Biol Chem 2006;281(15):10540–7.25. Younes A., Bartlett N. L., Leonard J. P. et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010;363(19):1812–21.Younes A., Bartlett N. L., Leonard J. P. et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010;363(19):1812–21.26. Chen R. W., Gopal A. K., Smith S. E. et al. Results of a pivotal phase II study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma (HL). J Clin Oncol 2011;29:8031.Chen R. W., Gopal A. K., Smith S. E. et al. Results of a pivotal phase II study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma (HL). J Clin Oncol 2011;29:8031.27. Pro B., Advani R., Brice P. et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012;30(18):2190–6.Pro B., Advani R., Brice P. et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012;30(18):2190–6.28. Kelly K. M., Hodgson D., Appel B. et al. Children’s Oncology Group’s 2013 blueprint for research: Hodgkin lymphoma. Pediatr Blood Cancer 2013;60(6):972–8.Kelly K. M., Hodgson D., Appel B. et al. Children’s Oncology Group’s 2013 blueprint for research: Hodgkin lymphoma. Pediatr Blood Cancer 2013;60(6):972–8.